Peloton Therapeutics’ approach to fighting kidney tumours has apparently convinced Merck & Co, which is to pay $1.05bn for the company on the back of relatively…
The group is desperately playing up mirvetuximab, but its future rests with a pair of earlier-stage projects.
While praising Novartis for kickstarting the CAR-T revolution, the chief exec of Tmunity has no doubt where cell therapy’s development engine really lies.
Amgen’s KRAS inhibitor, Macrogenics’ breast cancer project and Roche’s entrectinib stand out as the curtain lifts on thousands of abstracts due to be presented at the…
Two closely-watched liquid biopsy developers are to present data on their respective solid tumour blood tests.
Its gene therapy is three years away from market, but Mustang is already thinking about outcomes-based pricing.
The mere possibility of Guardant horning in on colorectal cancer has spooked Exact’s investors.
The companies’ DS-8201 succeeds in breast cancer patients who had failed Kadcyla, and will go before the regulators later this year.
The small-molecule oncology player zeroes in on its first commercial opportunity.